A detailed history of Jane Street Group, LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 269,948 shares of CERE stock, worth $0. This represents 0.01% of its overall portfolio holdings.

Number of Shares
269,948
Holding current value
$0
% of portfolio
0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.96 - $42.75 $10.5 Million - $11.5 Million
269,948 New
269,948 $11 Million
Q4 2023

Feb 14, 2024

BUY
$20.27 - $42.44 $4.3 Million - $9 Million
212,098 Added 513.23%
253,424 $10.7 Million
Q3 2023

Nov 14, 2023

SELL
$20.26 - $31.91 $1.9 Million - $3 Million
-93,864 Reduced 69.43%
41,326 $902,000
Q2 2023

Aug 14, 2023

BUY
$23.9 - $35.38 $2.2 Million - $3.26 Million
92,234 Added 214.72%
135,190 $4.3 Million
Q1 2023

May 15, 2023

BUY
$22.82 - $35.32 $762,986 - $1.18 Million
33,435 Added 351.17%
42,956 $1.05 Million
Q4 2022

Feb 14, 2023

BUY
$25.35 - $31.96 $241,357 - $304,291
9,521 New
9,521 $300,000
Q2 2022

Aug 16, 2022

SELL
$20.62 - $37.15 $483,209 - $870,573
-23,434 Closed
0 $0
Q1 2022

May 17, 2022

SELL
$23.5 - $35.38 $20,797 - $31,311
-885 Reduced 3.64%
23,434 $820,000
Q4 2021

Feb 15, 2022

SELL
$29.21 - $44.64 $39,229 - $59,951
-1,343 Reduced 5.23%
24,319 $788,000
Q3 2021

Nov 16, 2021

SELL
$21.26 - $38.85 $644,879 - $1.18 Million
-30,333 Reduced 54.17%
25,662 $757,000
Q2 2021

Aug 16, 2021

BUY
$12.56 - $29.69 $703,297 - $1.66 Million
55,995 New
55,995 $1.44 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.